secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0000950170-24-076474
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca initiates global Phase 3 SEACRAFT-2 trial for naporafenib + trametinib in NRAS-mutant melanoma
--------------------------------------------------------------------------------

- SEACRAFT-2 evaluates pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib vs trametinib alone.
- Stage 1 of the Phase 3 trial is expected to yield a randomized data readout in 2025.
- Trial targets NRAS-mutant melanoma, a setting with limited approved targeted therapies.
- Initiation marks the first Phase 3 trial for Erasca's wholly owned candidate naporafenib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024076474/0000950170-24-076474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024076474/eras-20240618.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-076474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer